Amplitude Surgical – Consolidated Annual Sales of €95.5 Million, +10% at Constant Exchange Rates
22 Juli 2021 - 6:00PM
Business Wire
- Consolidated annual sales of €95.5 million, +10.0 % at constant
exchange rates
- Activity impacted by the COVID-19 pandemic from October 2020
with a lesser global effect than the previous year
- Further strong growth in Novastep’s activity: +53.5% at
constant exchange rates
Regulatory news:
Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker:
AMPLI, eligible for PEA-PME plans) (“Amplitude” or the
“Group”), leading French player on the global surgical
technology market for lower-limb orthopedics, announces its
consolidated sales for its 2020-21 financial year.
Olivier Jallabert, Amplitude Surgical’s CEO, commented:
“Amplitude Surgical’s activity was impacted, during a large part of
last financial year and on most of its markets, by the public
health situation associated with COVID-19, and notably the adoption
of restrictions on access to operating rooms. Nevertheless, the
Group’s activity increased by 10.0% at constant exchange rates
compared with the previous year, which saw an almost total shutdown
in activity from mid-March 2020. Moreover, Novastep is continuing
its dynamic growth and now accounts for 13.4% of the Group’s sales,
with growth of 53.5% at constant exchange rates”.
Q4 2020-21
sales
30/06/2021
30/06/2020
Δ actual
Δ constant currency
€ thousands - IFRS
France
14,002
7,102
97.1%
97.1%
International
7,988
4,735
68.7%
71.3%
of which: subsidiaries
5,977
3,676
62.6%
65.9%
of which: distributors
2,012
1,060
89.8%
90.1%
Total
21,990
11,838
85.8%
86.8%
FY 2020-21
sales
30/06/2021
30/06/2020
Δ actual
Δ constant currency
€ thousands - IFRS
France
62,391
55,227
13.0%
13.0%
International
33,110
33,059
0.2%
5.2%
of which: subsidiaries
25,192
24,292
3.7%
10.5%
of which: distributors
7,919
8,767
-9.7%
-9.6%
Total
95,502
88,286
8.2%
10.0%
Over its 2020-21 financial year to June 30, 2021, Amplitude
Surgical recorded sales of €95.5 million, up 8.2% in actual terms
and 10.0% at constant currency. Activity was significantly impacted
on most of the Group’s markets from October 2020 by the situation
associated with COVID-19, with restrictions on access to operating
rooms resulting in the postponement of scheduled surgical
procedures. However, the impact was lower for the Group than it was
following the almost total shutdown of all activity in the final
quarter of the previous year.
During the final quarter of the recently ended financial year,
Amplitude Surgical’s activity was up by 86.8% at constant
currency.
- In France, annual sales totaled €62.4 million, up +13%.
During the year, activity was negatively impacted from the second
quarter by the successive waves of the COVID-19 pandemic, while the
previous year the negative impact only affected the final quarter
of the year, albeit to a greater extent. France accounted for 64%
of total annual sales;
- The Group’s international activity generated sales of
€33.1 million, a slight increase of 0.2% in actual terms and 5.2%
at constant currency. The Group’s subsidiaries recorded growth of
10.5% at constant currency to €25.2 million. Subsidiaries’ activity
was notably negatively impacted by the public health situation
associated with COVID-19 in Brazil and Germany and by the shutdown
in the Group’s activity in Japan, while Novastep’s activity in the
United States recorded strong growth. Activity with the Group’s
distributors fell by 9.6% to €7.9 million;
- Amplitude Surgical’s direct business (French market and
international subsidiaries), which accounts for almost 92% of the
Group’s total sales, increased by 12.2% at constant currency;
- Novastep, innovative solutions for foot and ankle
surgery, saw its annual sales further increase to €12.8 million
(+53.5% at constant currency). Novastep’s activity accounted for
13.4% of total Group sales.
Next financial press release 2020-21 annual results,
on Wednesday October 20, 2021, after market.
About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a
leading French player on the global surgical technology market for
lower-limb orthopedics. Amplitude Surgical develops and markets
high-end products for orthopedic surgery covering the main
disorders affecting the hip, knee and extremities, and notably foot
and ankle surgery. Amplitude Surgical develops, in close
collaboration with surgeons, numerous high value-added innovations
in order to best meet the needs of patients, surgeons and
healthcare facilities. A leading player in France, Amplitude
Surgical is developing abroad through its subsidiaries and a
network of exclusive distributors and agents distributing its
products in more than 30 countries. Amplitude Surgical operates on
the lower-limb market through the intermediary of its Novastep
subsidiaries in France and the United States. At June 30, 2021,
Amplitude Surgical had a workforce of 443 employees and recorded
sales of nearly 95.5 million euros.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210722005045/en/
Amplitude Surgical Dimitri Borchtch CFO finances@amplitude-surgical.com
+33 (0)4 75 41 87 41
NewCap Investor
Relations Mathilde
Bohin/Thomas Grojean amplitude@newcap.eu +33 (0)1 44 71 94
94
NewCap Media
Relations Nicolas
Merigeau amplitude@newcap.eu +33 (0)1 44 71 94 98
Amplitude Surgical (EU:AMPLI)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Amplitude Surgical (EU:AMPLI)
Historical Stock Chart
Von Apr 2023 bis Apr 2024